Articles related to MYELOMA

This study introduces a pivotal model that aids physicians in making informed decisions regarding bone marrow sampling for MGUS patients, utilizing a comprehensive set of biomarkers to predict the progression to SMM or worse conditions with high accuracy.

Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.

The study’s findings suggest that palliative radiotherapy could be a viable option for managing pain in multiple myeloma patients. With a complete response rate of 48% and a partial response rate of 38%, this treatment approach shows promise.

The FDA approval of motixafortide in combination with filgrastim offers a new, evidence-based approach to improve stem cell mobilization in multiple myeloma patients undergoing ASCT.

Discover how a recent class-action lawsuit against Bristol Myers Squibb could impact the availability and cost of multiple myeloma treatment options.

Discover how Elrexfio’s conditional FDA approval could redefine the treatment landscape for patients with difficult-to-treat multiple myeloma. Dive into the promising clinical trial results and understand its potential impact on your practice.